Giuseppe Colucci1, Tobias Silzle, Max Solenthaler. Show Affiliations » 1. Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland. giuseppe.colucci@insel.ch
Abstract
Entities: Chemical Disease
Mesh： See more » 5-Aminolevulinate Synthetase/antagonists & inhibitorsAnemia, Sideroblastic/bloodAnemia, Sideroblastic/chemically inducedAnemia, Sideroblastic/drug therapyAntitubercular Agents/administration & dosageAntitubercular Agents/adverse effectsAntitubercular Agents/therapeutic useAza Compounds/administration & dosageAza Compounds/therapeutic useBone Marrow/pathologyChemical and Drug Induced Liver Injury/etiologyDrug Therapy, CombinationEthambutol/administration & dosageEthambutol/therapeutic useFemaleFluoroquinolonesHemolysis/drug effectsHumansIsoniazid/administration & dosageIsoniazid/adverse effectsIsoniazid/therapeutic useMiddle AgedMoxifloxacinPeritonitis, Tuberculous/complicationsPeritonitis, Tuberculous/drug therapyPyrazinamide/administration & dosagePyrazinamide/adverse effectsPyrazinamide/therapeutic usePyridoxine/therapeutic useQuinolines/administration & dosageQuinolines/therapeutic useRifampin/administration & dosageRifampin/therapeutic usealpha-Thalassemia/complications
Substances： See more » Antitubercular AgentsAza CompoundsFluoroquinolonesQuinolinesPyrazinamideEthambutol5-Aminolevulinate SynthetaseALAS2 protein, humanPyridoxineMoxifloxacinIsoniazidRifampin
Year: 2011 PMID： 21818765 DOI： 10.1002/ajh.22125
Source DB: PubMed Journal: Am J Hematol ISSN： 0361-8609 Impact factor: 10.047